Bandar Kuching MP urges Fed govt to procure vaccine to grant better protection for children

Dr Kelvin Yii (file photo)

Follow and subscribe to DayakDaily on Telegram for faster news updates.


KUCHING, Nov 11: The Federal Government must consider changing Malaysia’s pneumococcal vaccine under the National Immunisation Programme (NIP) this year from the PCV10 pneumococcal vaccine which protects against fewer bacterial strains that the PCV13 vaccine, to give better protection to children against the more prevalent serotypes in our country.

This was the view of Bandar Kuching MP Dr Kelvin Yii, who brought up the issue in his budget debate to persuade the government to change their procurement approach when it came to this important vaccine, especially for Malaysian children.

“I am concerned the government will be ‘penny-wise, pound foolish’ especially since our children may be deprived of a better vaccine and that it may not achieves its target to provide adequate protection for our children from all common serotypes.


“Pneumonia kills more children than any other infectious disease, claiming the lives of over 800,000 children under five every year, or around 2,200 every day. In Malaysia, the incidence of invasive pneumococcal disease (IPD) is estimated at 3.8 per 100,000 cases each year,” said Dr Yii in a statement today.

He said, the most common pneumococcal detected in Malaysia is serotype 6A and 19A which is not covered under PCV10. In settings where disease attributable to serotype 19A or 6C is significant, PCV13 would have additional benefit as it contains additional serotype 3, 6A and 19A. PCV13 provides the broadest coverage of IPD consistently in most countries in Asia. In Malaysia, PCV13 provided 86.1 per cent serotype coverage of IPD serotypes in children below 5 years old in comparison to 62.9 per cent serotype coverage for the other pneumococcal vaccine (PCV10) in Malaysia.

Quoting the World Health Organisation (WHO), he said the choice of product to be used in a country should be based on programmatic characteristics, vaccine supply, vaccine price, the local and regional prevalence of vaccine serotypes and antimicrobial resistance patterns. In settings where disease attributable to serotype 19A or 6C is significant, PCV13 would have additional benefit as it contains additional serotype 3, 6A and 19A.

“In a cost-effectiveness analysis for Malaysia published in 2020, it was found that the introduction of PCV13 into the NIP in Malaysia for children aged 0–2 years is expected to not only reduce the overall disease burden but also contribute to significant savings from direct medical costs and indirect costs related to productivity loss as well as higher magnitude of net cost saving for the health system.

“Based on the study, the introduction of PCV13 in Malaysia National Immunisation Programme is estimated to reduce 4086 of invasive pneumococcal disease (IPD) cases, 160,833 cases of acute otitis media (AOM), 25,708 of pneumonia in comparison to PCV10 over a span of 5 years,” said Dr Yii.

He said the 2019 WHO Position Paper on “Pneumococcal Conjugate Vaccines in Infants and Children under 5 years of age” clearly states that while PCV 10 may be cheaper initially, when evaluated over a five-year period, PCV13 was estimated to save an additional RM665 million compared to the use of PCV10. This demonstrated significant cost saving potential as well as cost effectiveness of including PCV13 instead of PCV10 into the NIP.

“On top of that, PCV13 is the most widely used pneumococcal conjugate vaccine globally where currently it is introduced in NIPs in 133 countries with exclusivity in 127 countries. Several countries have switched from PCV10 to PCV13 in their NIP since 2015, including Peru, Armenia, Azerbaijan, Chile, Paraguay, Mozambique, Myanmar, Albania, Slovenia, Belgium, El Salvador and Austria

“So, I believe it is important the Health Minister makes the decision to change their procurement strategy and procure the PCV13 instead.

“The government must also clearly explains their initial decision to purchase PCV10 which includes greater transparency in the whole deal including the differences in cost for the purchase of PCV10 in comparison to PCV13, the company that was given the tender and was it done by open tender. This is important to make sure there will not be any wastage and that we can make sure that we provide the best coverage for our people,” said Dr Yii.  — DayakDaily